These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38954190)

  • 1. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase.
    Park D; Bea S; Bae JH; Lee H; Choe YJ; Shin JY; Kim H
    Drugs Real World Outcomes; 2024 Jul; ():. PubMed ID: 38954190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.
    Deng Z; Liu J; Gong H; Cai X; Xiao H; Gao W
    CNS Neurosci Ther; 2024 Apr; 30(4):e14522. PubMed ID: 37950531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 7. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
    Zhao X; Wu J; Zhu S
    Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®.
    Noseda R; Bedussi F; Panchaud A; Ceschi A
    Clin Pharmacol Ther; 2024 Aug; 116(2):346-350. PubMed ID: 38637956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the safety profiles of exogenous melatonin and associated adverse events: A pharmacovigilance study using WHO-VigiBase.
    Ha M; Yoon D; Lee CY; Lee M; Kim YW; Lee JM; Shin JY
    J Pineal Res; 2024 Mar; 76(2):e12949. PubMed ID: 38528668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
    Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
    Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
    Gouverneur A; Sanchez-Pena P; Veyrac G; Salem JE; Bégaud B; Bezin J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):271-276. PubMed ID: 34436707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Imbalzano E; Ilardi F; Orlando L; Pintaudi B; Savarese G; Rosano G
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):318-327. PubMed ID: 36972610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study.
    Blanco-Ruiz M; Amaya-Pascasio L; de Torres Chacón R; Álvarez Soria MJ; Arjona-Padillo A; Carrillo Bailén MM; Milán Pinilla R; Pérez Ortega I; Sánchez Rodríguez B; Andrade Zumárraga L; Valverde Moyano R; Payán Ortiz M; Castillo Fernández AM; Del Toro Pérez C; González Bustos P; Agüera Morales E; Sánchez López P; Hidalgo Martín B; Roa Chamorro R; Fernández Pérez J; Mejías Olmedo MV; Martínez-Sánchez P
    Atheroscler Plus; 2021 Nov; 45():32-38. PubMed ID: 36643997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
    Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
    Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.